| Year |
Citation |
Score |
| 2024 |
Tripathi AK, Desai PP, Tyagi A, Lampe JB, Srivastava Y, Donkor M, Jones HP, Dzyuba SV, Crossley E, Williams NS, Vishwanatha JK. Short Peptides based on the conserved regions of MIEN1 protein exhibit anti-cancer activity by targeting the MIEN1 Signaling Pathway. The Journal of Biological Chemistry. 105680. PMID 38272230 DOI: 10.1016/j.jbc.2024.105680 |
0.323 |
|
| 2023 |
Lampe JB, Desai PP, Tripathi AK, Sabnis NA, Chen Z, Ranjan AP, Vishwanatha JK. Cabazitaxel-Loaded Nanoparticles Reduce the Invasiveness in Metastatic Prostate Cancer Cells: Beyond the Classical Taxane Function. Pharmaceutics. 15. PMID 36839985 DOI: 10.3390/pharmaceutics15020662 |
0.451 |
|
| 2021 |
Rajendiran S, Maji S, Haddad A, Lotan Y, Nandy RR, Vishwanatha JK, Chaudhary P. MicroRNA-940 as a Potential Serum Biomarker for Prostate Cancer. Frontiers in Oncology. 11: 628094. PMID 33816263 DOI: 10.3389/fonc.2021.628094 |
0.495 |
|
| 2020 |
Hurtado M, Prokai L, Sankpal UT, Levesque B, Maram R, Chhabra J, Brown DT, Gurung RK, Holder AA, Vishwanatha JK, Basha R. Next generation sequencing and functional pathway analysis to understand the mechanism of action of copper-tolfenamic acid against pancreatic cancer cells. Process Biochemistry (Barking, London, England). 89: 155-164. PMID 32719579 DOI: 10.1016/J.Procbio.2019.10.022 |
0.41 |
|
| 2019 |
Patel K, Siraj S, Smith C, Nair M, Vishwanatha JK, Basha R. Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy. Critical Reviews in Oncogenesis. 24: 105-118. PMID 31679206 DOI: 10.1615/Critrevoncog.2019031417 |
0.327 |
|
| 2018 |
Hurtado M, Sankpal UT, Kaba A, Mahammad S, Chhabra J, Brown DT, Gurung RK, Holder AA, Vishwanatha JK, Basha R. Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 51: 1894-1907. PMID 30504717 DOI: 10.1159/000495715 |
0.305 |
|
| 2018 |
Van Treuren T, Vishwanatha JK. CRISPR deletion of MIEN1 in breast cancer cells. Plos One. 13: e0204976. PMID 30286132 DOI: 10.1371/Journal.Pone.0204976 |
0.328 |
|
| 2016 |
Mathew SO, Chaudhary P, Powers SB, Vishwanatha JK, Mathew PA. Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction. Oncotarget. PMID 27626681 DOI: 10.18632/Oncotarget.11896 |
0.634 |
|
| 2016 |
Rajendiran S, Gibbs LD, Van Treuren T, Klinkebiel DL, Vishwanatha JK. MIEN1 is tightly regulated by SINE Alu methylation in its promoter. Oncotarget. PMID 27589566 DOI: 10.18632/Oncotarget.11675 |
0.465 |
|
| 2016 |
Sankpal UT, Ingersoll SB, Ahmad S, Holloway RW, Bhat VB, Simecka JW, Daniel L, Kariali E, Vishwanatha JK, Basha R. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. PMID 27581819 DOI: 10.1007/S13277-016-5290-9 |
0.318 |
|
| 2016 |
Shetty P, Bargale A, Patil BR, Mohan R, Dinesh US, Vishwanatha JK, Gai PB, Patil VS, Amsavardani TS. Cell surface interaction of annexin A2 and galectin-3 modulates epidermal growth factor receptor signaling in Her-2 negative breast cancer cells. Molecular and Cellular Biochemistry. 411: 221-33. PMID 26438086 DOI: 10.1007/S11010-015-2584-Y |
0.307 |
|
| 2016 |
Vishwanatha J, Chaudhary P. Prostate metastasis promoter MIEN1 is tightly regulated by SINE Alu methylation in its promoter European Urology Supplements. 15: e1621. DOI: 10.1016/S1569-9056(16)30423-7 |
0.448 |
|
| 2016 |
Gdowski A, Ranjan A, Mukerjee A, Sarker M, Kimbell J, Vishwanatha J. MP84-11 BONE MICROENVIRONMENT TARGETED NANOPARTICLES FOR METASTATIC PROSTATE CANCER TREATMENT Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2235 |
0.448 |
|
| 2016 |
Shetty P, Bargale A, Patil BR, Mohan R, Dinesh US, Vishwanatha JK, Gai PB, Patil VS, Amsavardani TS. Cell surface interaction of annexin A2 and galectin-3 modulates epidermal growth factor receptor signaling in Her-2 negative breast cancer cells Molecular and Cellular Biochemistry. 411: 221-233. DOI: 10.1007/s11010-015-2584-y |
0.306 |
|
| 2015 |
Rajendiran S, Kpetemey M, Maji S, Gibbs LD, Dasgupta S, Mantsch R, Hare RJ, Vishwanatha JK. MIEN1 promotes oral cancer progression and implicates poor overall survival. Cancer Biology & Therapy. 16: 876-85. PMID 25996585 DOI: 10.1080/15384047.2015.1040962 |
0.374 |
|
| 2015 |
Griner NB, Young D, Chaudhary P, Mohamed AA, Huang W, Chen Y, Sreenath T, Dobi A, Petrovics G, Vishwanatha JK, Sesterhenn IA, Srivastava S, Tan SH. ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer. Molecular Cancer Research : McR. 13: 368-79. PMID 25344575 DOI: 10.1158/1541-7786.Mcr-14-0275-T |
0.623 |
|
| 2015 |
Chaudhary P, Vishwanatha JK. C-Jun NH<inf>2</inf>-terminal kinase-induced proteasomal degradation of c-FLIP<inf>L/S</inf> and Bcl<inf>2</inf> sensitize prostate cancer cells to Fas- and mitochondria-mediated apoptosis by tetrandrine Biochemical Pharmacology. 91: 457-473. PMID 25181458 DOI: 10.1016/J.Bcp.2014.08.014 |
0.565 |
|
| 2014 |
Rajendiran S, Parwani AV, Hare RJ, Dasgupta S, Roby RK, Vishwanatha JK. MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1. Molecular Cancer. 13: 250. PMID 25406943 DOI: 10.1186/1476-4598-13-250 |
0.615 |
|
| 2014 |
Gdowski A, Ranjan AP, Mukerjee A, Vishwanatha JK. Nanobiosensors: role in cancer detection and diagnosis. Advances in Experimental Medicine and Biology. 807: 33-58. PMID 24619617 DOI: 10.1007/978-81-322-1777-0_4 |
0.313 |
|
| 2012 |
Shetty PK, Thamake SI, Biswas S, Johansson SL, Vishwanatha JK. Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer. Plos One. 7: e44299. PMID 22957061 DOI: 10.1371/Journal.Pone.0044299 |
0.314 |
|
| 2012 |
Dasgupta S, Srinidhi S, Vishwanatha JK. Oncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges. Journal of Carcinogenesis. 11: 4. PMID 22438770 DOI: 10.4103/1477-3163.93001 |
0.608 |
|
| 2011 |
Dasgupta S, Cushman I, Kpetemey M, Casey PJ, Vishwanatha JK. Prenylated c17orf37 induces filopodia formation to promote cell migration and metastasis. The Journal of Biological Chemistry. 286: 25935-46. PMID 21628459 DOI: 10.1074/Jbc.M111.254599 |
0.338 |
|
| 2010 |
Das S, Shetty P, Valapala M, Dasgupta S, Gryczynski Z, Vishwanatha JK. Signal transducer and activator of transcription 6 (STAT6) is a novel interactor of annexin A2 in prostate cancer cells. Biochemistry. 49: 2216-26. PMID 20121258 DOI: 10.1021/Bi9013038 |
0.582 |
|
| 2009 |
Dasgupta S, Wasson LM, Rauniyar N, Prokai L, Borejdo J, Vishwanatha JK. Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells. Oncogene. 28: 2860-72. PMID 19503095 DOI: 10.1038/Onc.2009.145 |
0.635 |
|
| 2009 |
Braden AR, Kafka MT, Cunningham L, Jones H, Vishwanatha JK. Polymeric nanoparticles for sustained down-regulation of annexin A2 inhibit prostate tumor growth. Journal of Nanoscience and Nanotechnology. 9: 2856-65. PMID 19452941 DOI: 10.1166/Jnn.2009.028 |
0.431 |
|
| 2007 |
Das S, Roth CP, Wasson LM, Vishwanatha JK. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. The Prostate. 67: 1550-64. PMID 17705178 DOI: 10.1002/Pros.20640 |
0.581 |
|
| 2007 |
Braden A, Kashyap A, Vasir J, Labhasetwar V, Vishwanatha JK. Polymeric nanoparticles for sustained down-regulation of annexin A2 lead to reduction in proliferation and migration of prostate cancer cells Journal of Biomedical Nanotechnology. 3: 148-159. DOI: 10.1166/Jbn.2007.010 |
0.46 |
|
| 2007 |
Dasgupta S, Vishwanatha JK. Role of C17orf37/MGC14832 in prostate cancer cell proliferation and migration The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A289-B |
0.652 |
|
| 2005 |
Rothermund CA, Gopalakrishnan VK, Eudy JD, Vishwanatha JK. Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model. Bmc Urology. 5: 5. PMID 15790403 DOI: 10.1016/S1569-9056(03)80862-X |
0.727 |
|
| 2004 |
Rothermund CA, Gopalakrishnan VK, Vishwanatha JK. Androgen signaling and post-transcriptional downregulation of Bcl-2 in androgen-unresponsive prostate cancer. Prostate Cancer and Prostatic Diseases. 7: 158-64. PMID 15124003 DOI: 10.1038/Sj.Pcan.4500717 |
0.722 |
|
| 2004 |
Vishwanatha JK, Salazar E, Gopalakrishnan VK. Absence of annexin I expression in B-cell non-Hodgkin's lymphomas and cell lines. Bmc Cancer. 4: 8. PMID 15070421 DOI: 10.17925/Ohr.2005.00.00.1G |
0.508 |
|
| 2004 |
Vishwanatha J, Banerjee A, Liu J, Gopalakrishnan V. 456 Biomarkers modulating angiogenesis in prostate cancers from USA and India European Urology Supplements. 3: 116. DOI: 10.1016/S1569-9056(04)90453-8 |
0.589 |
|
| 2003 |
Banerjee AG, Bhattacharyya I, Lydiatt WM, Vishwanatha JK. Aberrant expression and localization of decorin in human oral dysplasia and squamous cell carcinoma. Cancer Research. 63: 7769-76. PMID 14633702 |
0.307 |
|
| 2003 |
Banerjee AG, Liu J, Yuan Y, Gopalakrishnan VK, Johansson SL, Dinda AK, Gupta NP, Trevino L, Vishwanatha JK. Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA. Molecular Cancer. 2: 34. PMID 14613585 DOI: 10.1186/1476-4598-2-34 |
0.568 |
|
| 2003 |
Liu J, Rothermund CA, Ayala-Sanmartin J, Vishwanatha JK. Nuclear annexin II negatively regulates growth of LNCaP cells and substitution of ser 11 and 25 to glu prevents nucleo-cytoplasmic shuttling of annexin II. Bmc Biochemistry. 4: 10. PMID 12962548 DOI: 10.1186/1471-2091-4-10 |
0.703 |
|
| 2003 |
Gopalakrishnan VK, Banerjee AG, Vishwanatha JK. Effect of FHIT gene replacement on growth, cell cycle and apoptosis in pancreatic cancer cells. Pancreatology : Official Journal of the International Association of Pancreatology (Iap) ... [Et Al.]. 3: 293-302. PMID 12890991 DOI: 10.1159/000071767 |
0.389 |
|
| 2002 |
Rothermund CA, Kondrikov D, Lin MF, Vishwanatha JK. Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer. Prostate Cancer and Prostatic Diseases. 5: 236-45. PMID 12496988 DOI: 10.1038/Sj.Pcan.4500582 |
0.739 |
|
| 2000 |
Guo Z, Johansson SL, Rhim JS, Vishwanatha JK. Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model. The Prostate. 43: 101-10. PMID 10754525 DOI: 10.1002/(Sici)1097-0045(20000501)43:2<101::Aid-Pros4>3.0.Co;2-A |
0.537 |
|
| 2000 |
Rothermund C, Vishwanatha J. Molecular Mechanisms of Apoptosis Regulation in Prostate Cancer Biochemical Society Transactions. 28: A382-A382. DOI: 10.1042/bst028a382a |
0.737 |
|
| 1999 |
Chiang Y, Rizzino A, Sibenaller ZA, Wold MS, Vishwanatha JK. Specific down-regulation of annexin II expression in human cells interferes with cell proliferation. Molecular and Cellular Biochemistry. 199: 139-47. PMID 10544962 DOI: 10.1023/A:1006942128672 |
0.303 |
|
| 1993 |
Vishwanatha JK, Chiang Y, Kumble KD, Hollingsworth MA, Pour PM. Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers Carcinogenesis. 14: 2575-2579. PMID 8269629 DOI: 10.1093/Carcin/14.12.2575 |
0.326 |
|
| Show low-probability matches. |